Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibrocell Provides Final Data To Resolve FDA Concerns On Its Autologous Stem Cell Therapy For Facial Wrinkles

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech hopes next to advance its technology into treatment of acne scarring; the laViv PDUFA date is June 22.

You may also be interested in...



Missing Mechanism Of Action Dogged Laviv Review

Absence of data about what happens under the surface of the skin when the cell therapy for wrinkles is injected raised safety concerns.

Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy

The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.

Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy

The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel